Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial
Georgina V. Long(The University of Sydney), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Margaret K. Callahan(Cornell University), Alicia Cheong(Bristol-Myers Squibb (United Kingdom)), Ahmad A. Tarhini(UPMC Hillman Cancer Center), Ioannis Thomas(Sensap (Greece)), Andrew Fisher(Boston University), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andréia Cristina de Melo(National Cancer Institute), Dirk Schadendorf(National Center for Tumor Diseases), Sunandana Chandra(Northwestern University), Peter Koelblinger(Paracelsus Medical University), Mark Semaan(Bristol-Myers Squibb (United States)), Eva Muñoz‐Couselo(Vall d'Hebron Hospital Universitari), Jun Guo(Soochow University), Bonnie Wang(Bristol-Myers Squibb (United States)), Charlie Garnett‐Benson(Bristol-Myers Squibb (United States)), Reinhard Dummer(University Hospital of Zurich), G. Quéreux(Nantes Université), Armand Chouzy(Bristol-Myers Squibb (United States)), Helen Gogas(National and Kapodistrian University of Athens), Patrick Djidel(Bristol-Myers Squibb (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Jia Xin Yu(Tisch Hospital), Sonia Dolfi(Bristol-Myers Squibb (United States))
Cited by 11
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k